These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
539 related articles for article (PubMed ID: 26344613)
1. All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis. Ogura T; Azuma A; Inoue Y; Taniguchi H; Chida K; Bando M; Niimi Y; Kakutani S; Suga M; Sugiyama Y; Kudoh S; Nukiwa T Respir Investig; 2015 Sep; 53(5):232-41. PubMed ID: 26344613 [TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study. Tzouvelekis A; Ntolios P; Karampitsakos T; Tzilas V; Anevlavis S; Bouros E; Steiropoulos P; Koulouris N; Stratakos G; Froudarakis M; Bouros D Pulm Pharmacol Ther; 2017 Oct; 46():48-53. PubMed ID: 28843616 [TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis: A Nationwide Post-Marketing Surveillance Study in Korean Patients. Chung MP; Park MS; Oh IJ; Lee HB; Kim YW; Park JS; Uh ST; Kim YS; Jegal Y; Song JW Adv Ther; 2020 May; 37(5):2303-2316. PubMed ID: 32297284 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan. Taguchi Y; Ebina M; Hashimoto S; Ogura T; Azuma A; Taniguchi H; Kondoh Y; Suga M; Takahashi H; Nakata K; Sugiyama Y; Kudoh S; Nukiwa T; Respir Investig; 2015 Nov; 53(6):279-87. PubMed ID: 26521105 [TBL] [Abstract][Full Text] [Related]
5. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena. Vietri L; Cameli P; Perruzza M; Cekorja B; Bergantini L; d'Alessandro M; Refini RM; Pieroni M; Fossi A; Bennett D; Spalletti M; Mazzei MA; Sestini P; Rottoli P; Bargagli E Ther Adv Respir Dis; 2020; 14():1753466620906326. PubMed ID: 32066332 [TBL] [Abstract][Full Text] [Related]
6. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients. Feng H; Zhao Y; Li Z; Kang J Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705 [TBL] [Abstract][Full Text] [Related]
7. Pirfenidone for the treatment of idiopathic pulmonary fibrosis. Xaubet A; Serrano-Mollar A; Ancochea J Expert Opin Pharmacother; 2014 Feb; 15(2):275-81. PubMed ID: 24308635 [TBL] [Abstract][Full Text] [Related]
8. A 2-Year Observational Study in Patients Suffering from Idiopathic Pulmonary Fibrosis and Treated with Pirfenidone: A French Ancillary Study of PASSPORT. Jouneau S; Gamez AS; Traclet J; Nunes H; Marchand-Adam S; Kessler R; Israël-Biet D; Borie R; Strombom I; Scalori A; Crestani B; Valeyre D; Cottin V Respiration; 2019; 98(1):19-28. PubMed ID: 30965332 [TBL] [Abstract][Full Text] [Related]
9. A safety evaluation of pirfenidone for the treatment of idiopathic pulmonary fibrosis. Anderson A; Shifren A; Nathan SD Expert Opin Drug Saf; 2016 Jul; 15(7):975-82. PubMed ID: 27177012 [TBL] [Abstract][Full Text] [Related]
10. A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study). Iwata T; Yoshino I; Yoshida S; Ikeda N; Tsuboi M; Asato Y; Katakami N; Sakamoto K; Yamashita Y; Okami J; Mitsudomi T; Yamashita M; Yokouchi H; Okubo K; Okada M; Takenoyama M; Chida M; Tomii K; Matsuura M; Azuma A; Iwasawa T; Kuwano K; Sakai S; Hiroshima K; Fukuoka J; Yoshimura K; Tada H; Nakagawa K; Nakanishi Y; Respir Res; 2016 Jul; 17(1):90. PubMed ID: 27450274 [TBL] [Abstract][Full Text] [Related]
11. Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. Costabel U; Albera C; Bradford WZ; Hormel P; King TE; Noble PW; Sahn SA; Valeyre D; du Bois RM Sarcoidosis Vasc Diffuse Lung Dis; 2014 Oct; 31(3):198-205. PubMed ID: 25363219 [TBL] [Abstract][Full Text] [Related]
12. Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis. Arai T; Inoue Y; Sasaki Y; Tachibana K; Nakao K; Sugimoto C; Okuma T; Akira M; Kitaichi M; Hayashi S Respir Investig; 2014 Mar; 52(2):136-43. PubMed ID: 24636270 [TBL] [Abstract][Full Text] [Related]
13. A multicentre retrospective observational study on Polish experience of pirfenidone therapy in patients with idiopathic pulmonary fibrosis: the PolExPIR study. Majewski S; Białas AJ; Buchczyk M; Gomółka P; Górska K; Jagielska-Len H; Jarzemska A; Jassem E; Jastrzębski D; Kania A; Koprowski M; Krenke R; Kuś J; Lewandowska K; Martusewicz-Boros MM; Roszkowski-Śliż K; Siemińska A; Sładek K; Sobiecka M; Szewczyk K; Tomczak M; Tomkowski W; Wiatr E; Ziora D; Żołnowska B; Piotrowski WJ BMC Pulm Med; 2020 May; 20(1):122. PubMed ID: 32366291 [TBL] [Abstract][Full Text] [Related]
14. Usefulness of a disease severity staging classification system for IPF in Japan: 20 years of experience from empirical evidence to randomized control trial enrollment. Homma S; Sugino K; Sakamoto S Respir Investig; 2015 Jan; 53(1):7-12. PubMed ID: 25542598 [TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257 [TBL] [Abstract][Full Text] [Related]
16. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment. Nathan SD; Costabel U; Albera C; Behr J; Wuyts WA; Kirchgaessler KU; Stauffer JL; Morgenthien E; Chou W; Limb SL; Noble PW Respir Med; 2019 Jul; 153():44-51. PubMed ID: 31153107 [TBL] [Abstract][Full Text] [Related]
17. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases. Oltmanns U; Kahn N; Palmowski K; Träger A; Wenz H; Heussel CP; Schnabel PA; Puderbach M; Wiebel M; Ehlers-Tenenbaum S; Warth A; Herth FJ; Kreuter M Respiration; 2014; 88(3):199-207. PubMed ID: 25115833 [TBL] [Abstract][Full Text] [Related]
18. An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP). Costabel U; Albera C; Lancaster LH; Lin CY; Hormel P; Hulter HN; Noble PW Respiration; 2017; 94(5):408-415. PubMed ID: 28898890 [TBL] [Abstract][Full Text] [Related]
19. Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone. Miura Y; Saito T; Tanaka T; Takoi H; Yatagai Y; Inomata M; Nei T; Saito Y; Gemma A; Azuma A Respir Investig; 2018 Jan; 56(1):72-79. PubMed ID: 29325685 [TBL] [Abstract][Full Text] [Related]
20. Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone. Kreuter M; Spagnolo P; Wuyts W; Renzoni E; Koschel D; Bonella F; Maher TM; Kolb M; Weycker D; Kirchgässler KU; Costabel U Respiration; 2017; 93(6):415-423. PubMed ID: 28399537 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]